CAMP4 Therapeutics Corp (CAMP) is a clinical-stage biopharmaceutical company focused on discovering and developing RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels in genetic diseases. Revenue comes from collaboration and license agreements, totaling $3.5 million in FY2025 and $0.7 million in FY2024. No product sales revenue has been generated as of the 10-K filed March 5, 2026. The lead program, CMP-002, is an intrathecally delivered antisense oligonucleotide targeting SYNGAP1-related disorder, a severe developmental and epileptic encephalopathy affecting an estimated 21,000 individuals in the United States and five largest European markets, for which no approved disease-modifying therapies exist. The company's RAP Platform underlies its pipeline and proprietary IP estate. Josh Mandel-Brehm serves as President and Chief Executive Officer.

Revenue model

Collaboration and license agreement revenue: $3.5 million in FY2025, $0.7 million in FY2024. No product sales revenue generated. Future revenue, if any, would come from product sales upon regulatory approval or payments from collaboration and license agreements.

Products and services

CMP-002: intrathecally delivered antisense oligonucleotide (ASO) targeting the SYNGAP1 gene to increase gene expression and restore SYNGAP protein levels, in development for SYNGAP1-related disorder. RAP Platform: proprietary RNA-targeting technology platform for upregulating gene expression.

Customers and end markets

End market: patients with rare genetic diseases, specifically SYNGAP1-related disorder (developmental and epileptic encephalopathy). Estimated patient population of approximately 21,000 in the United States and five largest European markets. Collaborators and licensors are counterparties to revenue-generating agreements.

Value-chain role

Drug discovery and clinical-stage development. Relies on contract research organizations (CROs) and contract manufacturing organizations (CMOs) for clinical trials and preclinical studies. Licenses foundational technology from the Whitehead Institute, with aggregate license maintenance and patent fees of approximately $0.9 million paid through December 31, 2025 under that agreement.

Geographic exposure

Headquartered in the United States. Target patient population identified in the United States and five largest European markets. No product commercialization geographic exposure disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-05

Industry: Pharmaceutical Preparations